pgp3 markers of chlamydia in HIV
This article was originally published in Clinica
Executive Summary
Testing for pgp3 could be an effective way to screen HIV and STD patients in studies on chlamydia-HIV interaction. Researchers from Laboratories of the HCM Chlamydia Network of the European Community, Amiens (France) and IRIS Research Centre, Chiron-Biocine Siena (Italy) report in The Lancet (September 20th) that they found an unexpectedly high prevalence (83%) of pgp3-positive responses in CtMIF-negative patients.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.